Skip to main content

Table 1 pCR in the overall cohort according to breast cancer subtypes

From: Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

Breast cancer subtype Patients without pCR (n, %) Patients with pCR (n,%)
Luminal A-like 893 (93.6) 61 (6.4)
Luminal B-like 329 (86.4) 52 (13.6)
HER2 positive 564 (69.7) 245 (30.3)
TNBC 629 (62.4) 379 (37.6)